Regeneron Forms Second RNAi Partnership with Alnylam
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 4 (Table of Contents)
Published: 22 Apr-2019
DOI: 10.3833/pdr.v2019.i4.2418 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In their second collaboration in a little over a year, Regeneron Pharmaceuticals has entered into a five-year alliance with Alnylam Pharmaceuticals to develop RNA interference therapies for 30 targets for the treatment of ocular and central nervous system diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS